Dr Gareth Jones
Inflammation and Cytokines Laboratory
The Jones laboratory investigates cytokine-regulated mechanisms that underpin chronic inflammation and immune-mediated tissue damage.
Inflammation is the body’s natural response to infection and tissue injury. Cytokines orchestrate all aspects of the inflammatory response including immune cell activation, migration, survival and effector function. Optimal control of this process ensures competent host defence. However, persistent or non-resolving episodes of inflammation often leads to tissue damage.
Our research examines how cytokines regulate the development, organisation, effector characteristics and maintenance of immune cells within inflamed tissues, with a particular interest in the negative regulation of inflammation to restore immune and tissue homeostasis.
With a primary focus in inflammatory arthritis, our research aims to exploit cytokines therapeutically and to define cytokine signatures that reflect patient outcomes.
Mission and impact
Our ultimate goal is to aid clinical decision-making through identifying diagnostic markers and novel therapies that can inform patient stratification and treatment.
Spanning basic, pre-clinical and early clinical studies, we are investigating novel drugs for the treatment for inflammatory diseases and cytokine signatures that reflect disease activity. We combine cell culture, in vivo disease models, analysis of clinical samples and ‘big data’ approaches (e.g., RNA-sequencing), thus linking basic mechanistic studies with translational outcomes.
A particular area of focus are the mechanisms that govern the development, organisation and activity of lymph node-like compartments (called ectopic lymphoid structures; ELS) that develop within chronically inflamed tissues. Our research considers cross-disease and disease-specific mechanisms that regulate ELS across autoimmunity, infection and cancer. Here, we propose that immunomodulation of cytokine networks holds real potential for the treatment of chronic diseases where ELS feature.
Qualifications and history
- 2019 - : Versus Arthritis Career Development Fellow. University of Bristol, UK
- 2019 - : Honorary Senior Research Fellow. Cardiff University, UK
- 2013 - 2018: Versus Arthritis Career Development Fellow. Cardiff University, UK
- 2011 - 2013: Postdoctoral Research Fellow. Cardiff University, UK
- 2010 - 2011: Versus Arthritis Travelling Fellow. Hudson (formerly Monash) Institute of Medical Research, Melbourne, Australia
- 2006 - 2010: Postdoctoral Research Associate. Cardiff University, UK
- 2006: PhD Biochemistry. School of Biosciences, Cardiff University, UK
- 2013: Recipient of a Versus Arthritis Career Development Fellowship
- 2013: Investigator Award, International Cytokine and Interferon Society (ICIS) congress, San Francisco, USA
- 2010: Recipient of a Versus Arthritis Travelling Fellowship
- 2009: Keystone Symposia Scholarship, Th17 Cells in Health and Disease conference, Vancouver, Canada.
- 2007: Postdoctoral Award, International Cytokine Society (ICS) congress, San Francisco, USA.
Please find further publications on Explore Bristol Research.
- Hill DG, Yu L, Gao H, Balic J,West A, Oshima H, McLeod L, Oshima M, Gallimore M, D’Costa K, Bhathal PS, Sievert W, Ferrero RL, Jenkins BJ and Jones GW (2018) Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. Int J Cancer. 143(1):167-178
- Patin EC, Jones AV, Thompson A, Clement M, Liao CT, Griffiths JS, Wallace LE, Bryant CE, Lang R, Rosenstiel P, Humphreys IR, Taylor PR, Jones GW* and Orr SJ* (2016). IL-27 Induced by Select Candida spp. via TLR7/NOD2 Signaling and IFN-beta Production Inhibits Fungal Clearance. J Immunol. 197:208-21
- Jones GW, Bombardieri M, Greenhill CJ, McLeod L, Nerviani A, Rocher-Ros V, Cardus A, Williams AS, Pitzalis C, Jenkins BJ and Jones SA (2015). Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J Exp Med. 212:1793-802
- Pitzalis C, Jones GW, Bombardieri M and Jones SA (2014). Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 14:447-62
- Fielding CA*, Jones GW*, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, Williams AS, Lambie M, Foster TL, Liao CT, Rice CM, Greenhill CJ, Colmont CS, Hams E, Coles B, Kift-Morgan A, Newton Z, Craig KJ, Williams JD, Williams GT, Davies SJ, Humphreys IR, O'Donnell VB, Taylor PR, Jenkins BJ, Topley N and Jones SA (2014). Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 40:40-50
My research has been generously funded by Versus Arthritis, Kidney Research UK, Medical Research Council (PhD studentship), Life Science Research Network Wales and through industrial partnerships.